Dirk Kreder

Dirk Kreder, anteris medical GmbH - Qepler Summits And Conferences

Dirk Kreder

Founder and CEO
anteris medical GmbH
Munich, Germany
anteris medical GmbH

Dirk Kreder is a Ph.D. from the life sciences by training and holds an International Executive MBA.

He worked more than 15 years for biotech and global pharma companies in the US, Switzerland, and Germany. Dirk is a seasoned expert in biotechnology industry. Prior to founding anteris, he spent 8 years on leading teams for development of complex generics and biosimilars. Thereafter his focus shifted to auto-injectors and combination products.

Dirk is committed in helping drug and device developers to optimize time-to-market and smooth regulatory approval process in a global environment. The focus of his main enterprise anteris medical GmbH is strategic positioning, development, and registration of combination products, such as prefilled syringes, inhalers, and autoinjectors, on behalf of pharmaceutical and biotech customers worldwide.

Related Sessions:

Qepler - Drug/Device Combination Products Summit thumbnail Details

Drug/Device Combination
Products Summit 2018

Get up to date with the regulatory and quality compliance strategies for combination product development.
  • 04 Dec 2018
  • Berlin, DE
  • Pharma
Day 1: Tuesday, 04 December 2018
BLOCK: REAL LIFE SOLUTIONS FOR YOUR COMBINATION PRODUCT.
CASE STUDY: Lifecycle Management of Combination Products.

Combination products, as the term implies, draw from the pharmaceutical and the medical device industries, and force developers and regulators into a complex and challenging evaluation of opportunities and risks. From a commercial perspective, market players act to prolong the commercial life of a product, counter a competitor’s move, increase the products value by offering additional value to the patient, or simply bring a product up to the standard of care. Whatever the change to the product, a series of regulatory, commercial, or supply chain consequences have to be considered to make the effort successful. The presentation is intended to provide insights into the highly dynamic LCM strategie for biologics and biosimilars.

View Details
This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Cookies Policy.